Mechanical Downsizing of a Gadolinium(III)-based Metal-Organic Framework for Anticancer Drug Delivery
A GdIII‐based porous metal–organic framework (MOF), Gd‐pDBI, has been synthesized using fluorescent linker pDBI (pDBI=(1,4‐bis(5‐carboxy‐1H‐benzimidazole‐2‐yl)benzene)), resulting in a three‐dimensional interpenetrated structure with a one‐dimensional open channel (1.9×1.2 nm) filled with hydrogen‐b...
Saved in:
Published in | Chemistry : a European journal Vol. 20; no. 33; pp. 10514 - 10518 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Weinheim
WILEY-VCH Verlag
11.08.2014
WILEY‐VCH Verlag Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A GdIII‐based porous metal–organic framework (MOF), Gd‐pDBI, has been synthesized using fluorescent linker pDBI (pDBI=(1,4‐bis(5‐carboxy‐1H‐benzimidazole‐2‐yl)benzene)), resulting in a three‐dimensional interpenetrated structure with a one‐dimensional open channel (1.9×1.2 nm) filled with hydrogen‐bonded water assemblies. Gd‐pDBI exhibits high thermal stability, porosity, excellent water stability, along with organic‐solvent and mild acid and base stability with retention of crystallinity. Gd‐pDBI was transformed to the nanoscale regime (ca. 140 nm) by mechanical grinding to yield MG‐Gd‐pDBI with excellent water dispersibility (>90 min), maintaining its porosity and crystallinity. In vitro and in vivo studies on MG‐Gd‐pDBI revealed its low blood toxicity and highest drug loading (12 wt %) of anticancer drug doxorubicin in MOFs reported to date with pH‐responsive cancer‐cell‐specific drug release.
MOF nanocarrier: A new GdIII‐based porous metal–organic framework, Gd‐pDBI, with an elongated rotatable linker (DBI=(1,4‐bis(5‐carboxy‐1H‐benzimidazole‐2‐yl)benzene) was synthesized. Gd‐pDBI is biocompatible, water‐stable, and acid/base‐tolerant. Mechanical grinding yielded nanocrystals with excellent water dispersibility, and they feature the highest loading of the anticancer drug doxorubicin (DOX) and cancer‐cell‐specific drug release. |
---|---|
Bibliography: | istex:C29270D8F0B834603636DC4F6E57773192B1E163 DFG ark:/67375/WNG-PN3GDF18-7 DBT National Fund (ICAR) BRNS CSIR - No. CSS0102; No. CSS0122 UR ArticleID:CHEM201402244 NAIP ISI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0947-6539 1521-3765 1521-3765 |
DOI: | 10.1002/chem.201402244 |